VenoVision provides the missing non-invasive advanced cardiac monitoring needed to improve the lives of millions of heart failure and at-risk patients.
VenoVision brings the power of ICU cardiac monitoring to lower resource settings, giving medical teams the hemodynamic data needed to adjust therapy in time to reduce ICU admissions and hospitalizations. VenoVision is a low cost, easy-to-use, thermal imaging-based hemodynamic monitoring device and platform for the entire continuum of care - inpatient, outpatient and home settings. It uniquely overcomes the challenges of monitoring obese patients.
The company is focused on driving down the billions of dollars currently spent on preventable deterioration and rehospitalizations. It has completed a proof-of-concept clinical trial, designed a prototype, and patented its technology. VenoVision was conceptualized in the Hebrew University of Jerusalem's BioDesign program, was a MassChallenge Israel 2021 Finalist, and is a Health Wildcatters Dallas accelerator (Dallas, USA) 2022 portfolio company. VenoVision won "most innovative" award at M2D2 Impact 2023.